Status:
COMPLETED
Elocon vs Fluticasone in Localized Psoriasis (P03197)
Lead Sponsor:
Organon and Co
Conditions:
Psoriasis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This is an open-label, randomized, parallel-group clinical study. The primary objective is to assess the difference in response rate between mometasone furoate cream 0.1% (once daily) vs fluticasone p...
Eligibility Criteria
Inclusion
- \>=18 years of age
- Written informed consent
- Having localized psoriasis (not more than 5-6 patches)
- Total size of all patches should be below 8" x 8"
- Each patient should exhibit any of the following 4 signs of dermatoses:
- erythema
- palpability
- scaling
- itching (pruritus)
- Each of the above signs would be grades according to the following scale:
- 0 = none
- = slight
- = moderate
- = severe The total Disease Severity Score (ie, the sum of the scores for each of the signs) should be at least 6 (indicative of a moderate to severe disease status)
Exclusion
- Pregnancy or lactation
- Hypersensitivity to any of the components of the test medication
- Signs of atrophy in the target area
- Lesions on palms, soles, and scalp
- Individuals who may require medications that might affect the natural course of the disease
- Not having used systemic corticosteroids or antimetabolites or any other topical corticosteroid within 2 weeks prior to enrollment in the study
- Concomitant tuberculosis/viral infection
Key Trial Info
Start Date :
January 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2005
Estimated Enrollment :
245 Patients enrolled
Trial Details
Trial ID
NCT00763529
Start Date
January 1 2003
End Date
January 1 2005
Last Update
August 15 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.